Introduction
Imatinib greatly reduces the number of leukemia cells in almost all patients with Philadelphia (Ph) chromosome-positive chronic myeloid leukemia (CML) and has revolutionized treatment for newly diagnosed patients. In previously untreated patients with chronic phase CML who receive imatinib the incidence of complete cytogenetic remission (CCyR) exceeds 80%, 1 and early analyses suggest that responding patients may survive considerably longer than they would have done with the best therapy available in the 1990s. 2 Imatinib acts by inhibiting the kinase activity of the Bcr-Abl oncoprotein, thereby reversing the activation of the signal transduction pathway that underlies the leukemia; 3 this in turn leads to death of affected cells. However, an appreciable minority of those patients who respond initially to imatinib subsequently lose their response in association with emergence of an imatinib-resistant clone. 4, 5 The various mechanisms underlying this resistance are probably heterogeneous but one that is reasonably well defined is the expansion of leukemia subclones with mutations in the Bcr-Abl kinase domain (KD) that impair imatinib binding. [6] [7] [8] [9] The identification of such mutations, especially those present in the phosphatebinding loop (P-loop) of the KD, appears in some series to be associated with a high probability of disease progression and relatively short survival. 10, 11 The in vivo kinetics of these mutated clones has not yet been extensively studied and it is unclear whether the observed mutations are the actual 'cause' of the resistance in every patient. To clarify this issue, we used pyrosequencing to monitor the levels of non-mutated and mutant BCR-ABL transcripts over time in a small series of patients with KD mutations.
Materials and methods

Patients studied
We sought mutations in the Bcr-Abl KD in 305 patients treated with imatinib in various phases of CML and identified 35 mutations in 34 individuals (11.1%); two mutations were identified in one of these patients (Table 1 ). In 12 of these cases (seven male, five female) we had available four or more sequential samples (median 9.5, range 4-19) collected while the patients' only anti-leukemia therapy was imatinib. Of these 12 patients, 11 were in chronic phase and one was in accelerated phase at the time of starting imatinib. Seven patients had previously received interferon-alfa and, in some cases, additional agents, and five were newly diagnosed. Two patients (patient nos. 5 and 12) achieved CCyR before the mutations were detected (Table 2) .
cDNA synthesis and sample analysis A cell pellet was prepared from 10 to 20 ml peripheral blood and/or from 2 to 3 ml of bone marrow aspirate, both of which had been collected into EDTA or preservative-free heparin as previously described. 12 Total RNA was extracted using a commercially available kit (Qiagen, Crawley, UK) and reverse transcribed to cDNA using MMLV reverse transcriptase. 12 BCR-ABL transcript numbers were then analyzed by real-time quantitative polymerase chain reaction as part of the routine monitoring of the patient's response to treatment as described elsewhere. 5, 13, 14 A search for Bcr-Abl KD mutations was undertaken at the same time.
The normal ABL allele was excluded from mutational analysis by amplifying a BCR-ABL amplicon from exon 13 of the BCR gene to exon 10 of the ABL gene using primers B2A and JAMR ( Figure 1 ). This amplicon template was then subjected to nested primer PCR to generate fragments of varying lengths, including an 863 bp fragment containing the entire Bcr-Abl KD for direct sequencing. Aliquots of the same amplicon were also subjected to amplification with biotinylated primers to generate PCR products containing the putative point mutation identified by direct sequencing. The biotinylated amplicons were tested for the mutation by pyrosequencing (Figure 1 ).
Direct sequencing
The BCR-ABL amplicon from each subject in the study was subjected to nested primer PCR using primers NTPB þ and NTPEÀ (see Figure 1) to generate an 863-bp fragment containing the entire Bcr-Abl KD. An aliquot of the PCR products was electrophoresed through 2.0% agarose gel; if a single amplicon was observed the remaining PCR products were purified using Magna-PCR clean up kit in accordance with the manufacturer's instructions (DNA Research Innovations, Sittingbourne, UK). Otherwise the PCR fragment containing the Abl KD was isolated using commercially available gel purification kit (Qiagen, UK) as recommended by the manufacturer. The purified amplicons were then subjected to Sanger's dideoxy chain termination reaction using a Big-Dye ABI 310 sequencer (Applied Biosystems, Foster City, USA). The reaction was primed with oligonucleotides shown in Figure 1 . In each case the sequence Table 1 Details of the BCR-ABL mutations and disease phase at the time of mutation detection for 34 patients in whom mutations were identified initially by direct sequencing Varying kinetics of BCR-ABL mutant clones JS Khorashad et al obtained was compared with the published ABL type 1a sequence, GenBank M14752, using BLAST 2 software. All observed base substitutions were confirmed by sequencing the complementary strand.
Pyrosequencing
When a BCR-ABL mutation was detected by direct sequencing in a patient for whom we had three or more previous cDNA samples, these were subjected to pyrosequencing [15] [16] [17] in accordance with the manufacturer's instructions (Pyrosequencing AB, Uppsala, Sweden). The BCR-ABL amplicon was used as a template for nested PCR using primers that flanked the region containing the putative mutation. One of the primers for each reaction was biotinylated (see Figure 1 ). Each cDNA was tested in duplicate. In brief, a single-stranded DNA template was isolated by combination of alkali denaturation and mixing biotinylated PCR products with streptavidin-coated sepharose beads (GE Healthcare, Amersham, UK). The pyrophosphate released on incorporation of a complementary nucleotide to the sequencing primer was converted to adenosine 5 0 triphosphate (ATP) by sulfurylase. The ATP generated was utilized as a coenzyme for luciferase that oxidizes luciferin to oxyluciferin and thereby emits light. The intensity of the light is proportional to the level of the single nucleotide polymorphism (Q-SNP) in a given sample. The percentages of mutant and non-mutated alleles were determined by the Allele Quantitation Algorithm using the PSQ t MA software (Pyrosequencing AB, Uppsala, Sweden).
The linearity of Q-SNP by pyrosequencing was tested by subjecting cDNA generated from graded mixes of Ba/F3 cell lines transfected with BCR-ABL cDNAs containing either the wild-type ABL sequence (BaF3/BCR-ABL) or the E255K mutation (BaF3/BCR-ABL E255K ). 18, 19 The mixes ranged from 10 to 100% BCR-ABL E255K (Figure 2 ). To ensure reproducibility, the cDNA synthesized from each mix was tested in triplicate by Q-SNP.
Results
Assay sensitivity
Titration of the proportion of mutant cells that could be detected in mixes of non-mutated and mutant BaF3-transfected cells revealed Q-SNP by pyrosequencing to be highly linear. Significantly, Q-SNP was observed to be more sensitive than Sanger's dideoxy chain termination reaction when the same cDNA was tested by the two methods (data not shown). Thus, a mutated BCR-ABL transcript could be detected by pyrosequencing when there were at least 10% mutant cells in the mixture, whereas in most cases this was not revealed by direct sequencing when less than 30% of the mix was comprised of mutant cells ( Figure 2) ; on occasion, however, direct sequencing was able to detect the presence of a mutation at considerably o30%.
Screening for kinase domain mutations
Kinase domain mutations were identified by direct sequencing in 34 of the 305 patents in various phases of CML (Table 1) , and were confirmed in each case by pyrosequencing. The total number of different mutations was 18; one patient had two different mutations.
Kinetics of total and mutant BCR-ABL transcripts
Twelve of the 34 patients had four or more cDNA specimens available for further study by pyrosequencing. In these patients, six different BCR-ABL mutations were detected spanning the entire Bcr-Abl KD. The commonest was the M244V substitution, detected in five (41%) of the patients (Table 3) . Three patients had mutations in the P-loop at positions 250 and 253. The other four mutations were distributed between positions 317 and 438. In two of these 12 patients (patient nos. 6 and 11, Table 2 ) our retroactive use of pyrosequencing demonstrated the presence of the mutation before treatment with imatinib was initiated.
In these 12 patients, we monitored the kinetics and interrelationship of the clones expressing the non-mutated and mutant transcripts respectively over periods ranging from 11 to 58 months (median 30.5 months). It was possible to classify patients into three groups on the basis of the pattern of changes over time in total and mutant BCR-ABL transcript numbers ( Table 3) . Examples of these three patterns are shown in Figure 3 .
In four of these patients (patient nos. 1 to 4) the total level of BCR-ABL transcripts initially fell and then recovered (patient nos. 1 and 4) or never fell to any appreciable extent (patient nos. 2 and 3), reflecting simply replacement of non-mutated by mutant transcripts (Group 1). In four other patients (patient nos. 5-8) the total number of transcripts had fallen considerably by the end of the period of observation (Group 2). In both groups the mutant clone increased and eventually represented the dominant population, but in Group 2 patients the total numbers of BCR-ABL transcripts remained low, whereas in Group 1 patients the total transcripts numbers remained at a level consistent with Ph-chromosome positivity.
In the third group of four patients (patient nos. 9-12) the proportion of mutant transcripts remained low or increased without ever exceeding an arbitrary 60% of total transcript numbers, whereas the numbers of non-mutated transcripts remained relatively high in two patients but fell to low levels in the other cases. In these patients it appears that the mutant Bcr-Abl clone had no significant proliferative advantage over the relatively resistant non-mutated cells and therefore remained relatively small.
Discussion
We describe here the use of a sensitive technique for measuring serially the proportion of mutant BCR-ABL transcripts in the We show that whereas some patients (Group 1) had persistently high total numbers of transcripts, the bulk of which were characterized by a specific Bcr-Abl KD mutation, two other patterns were also seen. In some patients, a mutant clone predominated but the total number of BCR-ABL transcripts remained low, at a level consistent with continuing CCyR (Group 2). In other patients, the total number of transcripts remained high (consistent with persisting Ph-positivity) or fell to low levels, while the proportion of mutant transcripts was low when first detected and did not rise appreciably during the period of observation (Group 3). It should be noted that two patients in this study, one of whom was in Group 3, had a G250E mutation which is highly resistant to imatinib in vitro; one patient had a Y253H mutation which is also relatively resistant; the other mutations have all been reported as Table 3 Summary of clinical events for 12 patients after the mutation was detected (a) Group 1 -patient no. 3 studied serially over 15 months never achieved a reduction greater than 1 log in total transcripts. The last three values showed that the mutant transcripts (coding for M244V) were 100%. (b) Group 2 -patient no. 8 studied serially over 42 months showed a major and persisting reduction in total numbers of BCR-ABL transcripts. However, the latest value showed that these transcripts were 100% mutant (coding for S438C). (c) Group 3 -patient no. 9 studied serially over 43 months only achieved a very minimal reduction in total transcript numbers. A mutant transcript (coding for G250E) was detected at low level at the start of imatinib treatment, and the level remained relatively static during the entire period of follow-up.
substantially more resistant than unmutated Bcr-Abl. 9, 18 Thus, in some cases the relationship between clinical observations and in vitro studies is not perfect.
We speculate that whereas the KD mutations observed in Group 1 patients might have been the direct 'cause' of the imatinib resistance, it is difficult to draw the same conclusion for patients in Groups 2 and 3. In Group 2 patients the total level of BCR-ABL transcripts did not differ appreciably from levels observed in patients in CCyR in whom no mutation has been detected; this implies that the mutation was not the 'cause' of the persisting low-level residual disease. In Group 3 patients, the great majority of the BCR-ABL transcripts present at a high level were apparently non-mutated, which suggests that the mutant clone present at low level probably played no significant role in the observed resistance to imatinib.
The association of imatinib resistance with mutations in the ABL component of the BCR-ABL gene was first reported in 2001. 6 Subsequently, mutations coding for up to 30 amino-acid substitutions have been described, 8, 10, 20, 21 and the eight most common, including those involving Y253, E255, T315, M351 and F359, account for 60-70% of all mutations, although the actual frequencies differ substantially in different series. [9] [10] [11] 22, 23 This varying frequency is well exemplified in this study of KD mutations in 34 patients; mutations involving M244 were surprisingly frequent, whereas we saw no example of the T315I mutation reported regularly in other series. Structural data suggest that some of these mutations interfere with imatinib binding by interrupting critical contact points in the KD or by maintaining a molecular conformation that impedes drug binding. 8, [23] [24] [25] Abl kinases with some specific mutations are apparently totally insensitive to pharmacological levels of imatinib while others show partial or little resistance. 18 Our finding and that of others 26, 27 that small mutant clones were detectable in some patients before administration of imatinib support the assumption that the larger mutant clones observed after treatment reflect selective expansion under the influence of the inhibitor of a small pre-existing mutant population, and are not the direct result of a mutagenic effect of the drug. In some patients, the finding of mutations in the Abl KD, especially those in the P-loop, has been associated with increased risk of disease progression and it has been implied that the relationship might be 'causal.' 10 However, it is in fact difficult to see how exactly a KD mutation that interferes with the action of imatinib could directly expedite disease progression, although it is clear from ex vivo studies that specific Abl mutations do increase the transforming capacity of the oncoprotein 28 (Griswold et al., Blood 2004; 104: 161, abstract #555).
Willis et al. 22 recently reported the results of searching for eight specific mutations in the Abl KD using a high sensitivity allele-specific oligonucleotide-PCR in 66 CML patients not previously exposed to imatinib. They found mutations, generally at low level, in 13 of the patients with advanced phase disease but in none of those with chronic phase. There was no correlation between the presence of a mutation and subsequent response to imatinib, although there was a significant correlation with previous exposure to 6-thioguanine, a known mutagenic agent. These findings and those described in this paper are consistent with the notion that mutations in the Abl KD occur spontaneously (or as a result of treatment with specific drugs) throughout the course of the disease, but in many cases the mutated clone remains small. Specific clones with mutations that interfere with imatinib binding may expand when patients are treated with this drug, but other mutant clones may derive no selective advantage during imatinib treatment. It is possible that some mutant clones that expand and eventually constitute the bulk of the Ph-positive population enhance 'genomic instability' and thereby increase the risk of disease progression. However, it is equally possible that other clones detected at low level in chronic phase merely reflect the intrinsic instability of the Ph-positive cell population, which may well differ from patient to patient, but do not of themselves increase the risk of further leukemic transformation.
Although the majority of patients with CML in chronic phase respond extremely well to imatinib and achieve CCyR, some do not. Moreover, in a small proportion of patients BCR-ABL transcripts become undetectable, but in others the levels of residual disease are variable. 5 Thus, the response to imatinib varies in different patients and even varies in patients who acquire the same Bcr-Abl KD mutation. For example, in this series, patient no. 3 with an M244V mutation failed to respond to increased doses of imatinib, while patient no. 7 with the same mutant clone did respond. Thus, it seems likely that other mechanisms that operate in a patient still in chronic phase, such as overexpression of BCR-ABL, 29 of MDR 30 or of LYN, 31 may be more important in causing imatinib resistance than the observed KD mutation. These observations provide further support for the basic heterogeneity of CML in chronic phase -a heterogeneity that is likely to be intrinsic to the disease or to reflect some component of the patient's genetic make-up. Thus one major challenge in the study of CML is to characterize further the basis for this 'intrinsic' heterogeneity.
